Printed from Voxsanity (voxsanity.com.au) — NCT07495124 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Ovarian Cancer
Phase 2 Ovarian Cancer Trial, Recruiting
NCT07495124
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer and have already received chemotherapy that included a platinum-based drug.
- People whose CA-125 blood marker (a marker used to monitor certain cancers) returned to normal after their first course of treatment.
- People whose CA-125 level has since risen to more than twice the upper limit of the normal range, or more than twice its lowest recorded level, after their most recent second or later round of treatment.
- People who do not have measurable tumour areas visible on scans, based on a standard measurement system called RECIST 1.1 (fluid build-up in the abdomen or around the lungs does not count as measurable disease if it is not causing symptoms).
- People who are sexually active in a way that could lead to pregnancy must agree to use an accepted form of contraception for the full duration of the study, including a one-year follow-up period (accepted methods include condoms with contraceptive foam, oral, implantable or injectable contraceptives, a contraceptive patch, an intrauterine device, a diaphragm with spermicidal gel, or having a partner who has been surgically sterilised or has gone through menopause).
- People who are expected to live for at least 3 months.
- People who are willing and able to give written consent to take part in the trial.
- People who are 18 years of age or older at the time of signing the consent form.
- People who are in generally good physical condition, rated 0 or 1 on a standard medical scale called the ECOG performance scale (confirm with trial site).
- People whose white blood cell count is at or above a level of 3000/mm³, tested within 14 days before starting treatment.
- People whose haemoglobin level (a measure of red blood cells carrying oxygen) is at or above 10 g/dl, tested within 14 days before starting treatment.
- People whose haematocrit level (another measure of red blood cell volume) is at or above 28%, tested within 14 days before starting treatment.
- People whose kidney function measurements (serum creatinine and creatinine clearance) are within acceptable ranges, tested within 14 days before starting treatment (confirm with trial site for exact values).
- People whose total bilirubin level (a liver-related marker) is at or below 2.5 mg/dl, tested within 14 days before starting treatment.
- People whose AST level (a marker of liver health) is no more than 3 times the upper limit of the normal range, tested within 14 days before starting treatment.
- People whose blood sugar level is below 1.5 times the upper limit of the normal range, tested within 14 days before starting treatment.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who are currently taking part in another clinical trial involving an experimental treatment, or who have received an experimental treatment within the past 4 weeks.
- People who have been diagnosed with a condition that weakens the immune system, or who are taking steroid medications at a dose above 10 mg per day of prednisone (or equivalent), or any other immune-suppressing medication within 7 days before the first dose of trial treatment.
- Short-term use of steroids for allergic reactions or to manage side effects from other treatments is permitted.
- People who have uncomfortable or symptomatic fluid build-up in the abdomen or around the lungs.
- People with a history of borderline or low malignant potential ovarian cancer.
- People who have received a type of cancer treatment called a monoclonal antibody within 4 weeks before the trial start date, or who have not yet recovered from side effects of such treatments given more than 4 weeks ago.
- People who have received chemotherapy, biological therapy, targeted therapy, hormonal therapy, or radiation therapy within 2 weeks before the trial start date, or who have not yet recovered from side effects of those treatments (people with mild nerve-related side effects at grade 2 or below may still be considered — confirm with trial site; people who have had major surgery must have recovered sufficiently before starting).
- People who have another cancer that is currently growing or requires active treatment, with the exception of certain treated skin cancers (basal cell or squamous cell carcinoma) or cervical cancer that has not spread.
- People who have active cancer that has spread to the brain or the lining of the brain and spinal cord (carcinomatous meningitis is excluded regardless of stability; people with previously treated and stable brain metastases that have not grown for at least 4 weeks and who have not needed steroids for at least 14 days may still be considered — confirm with trial site).
- People who have an autoimmune disease that has required systemic medical treatment within the past 2 years (routine hormone or gland replacement therapy is not considered systemic treatment for this purpose).
- People who have an active infection that requires treatment with medication.
- People who have any condition, treatment history, or abnormal test result that, in the treating doctor's opinion, could interfere with the trial or would not be in the person's best interest.
- People who are pregnant, breastfeeding, or planning to become pregnant during the trial period, from the initial screening visit through to 120 days after the last dose of trial treatment.
- People with clinically significant heart or blood vessel disease.
- People who have had a severe allergic reaction (grade 3 or higher) to the drug carboplatin, any history of a severe sudden allergic reaction (anaphylaxis), or asthma that is not well controlled.
- People for whom there is a medical reason they should not receive a type of medication called rhuGM-CSF (a drug that supports white blood cell production) (confirm with trial site).
- People who have a known history of HIV (Human Immunodeficiency Virus).
- People who have known active hepatitis B or hepatitis C infection.
- People who have received a live or live-attenuated vaccine within 30 days before the planned start of trial treatment (non-live/inactivated vaccines are permitted; standard injected flu vaccines are generally allowed, but nasal spray flu vaccines such as Flu-Mist® are not).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Principal Investigator: John Liao, MD, PhD, Fred Hutch/University of Washington Cancer Consortium
Phone: 1-866-932-8588
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
1 October 2026
Est. completion
29 September 2027
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
Progression free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.